|
Active substance |
Pembrolizumab - MK 3475 |
|
Holder |
MSD |
|
Status |
Closed |
|
Indication |
In combination with chemotherapy (carboplatin + paclitaxel) for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 with a tumour proportion score (TPS) between l%-49% or no PD-L1 (TPS <1%). |
|
Public documents |
|
|
Dernière mise à jour |
04/04/2019 |
Keytruda®
Last updated on 10/09/2024